NZ506598A - Methods for treating conditions mediated by integrin alpha-and beta subunits, aka the vitronectin receptor - Google Patents
Methods for treating conditions mediated by integrin alpha-and beta subunits, aka the vitronectin receptorInfo
- Publication number
- NZ506598A NZ506598A NZ506598A NZ50659899A NZ506598A NZ 506598 A NZ506598 A NZ 506598A NZ 506598 A NZ506598 A NZ 506598A NZ 50659899 A NZ50659899 A NZ 50659899A NZ 506598 A NZ506598 A NZ 506598A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mimosa
- printed
- added
- pct
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3427098A | 1998-03-04 | 1998-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ506598A true NZ506598A (en) | 2003-07-25 |
Family
ID=21875345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ506598A NZ506598A (en) | 1998-03-04 | 1999-02-22 | Methods for treating conditions mediated by integrin alpha-and beta subunits, aka the vitronectin receptor |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1060164A1 (uk) |
| JP (1) | JP2002505323A (uk) |
| KR (1) | KR20010041584A (uk) |
| CN (1) | CN1214011C (uk) |
| AP (1) | AP1244A (uk) |
| AR (1) | AR018139A1 (uk) |
| AU (1) | AU753230B2 (uk) |
| BG (1) | BG104740A (uk) |
| BR (1) | BR9908470A (uk) |
| CA (1) | CA2322207A1 (uk) |
| EA (1) | EA200000804A1 (uk) |
| EE (1) | EE200000506A (uk) |
| GE (1) | GEP20033118B (uk) |
| HR (1) | HRP20000574A2 (uk) |
| HU (1) | HUP0100865A3 (uk) |
| ID (1) | ID25591A (uk) |
| IL (1) | IL137653A0 (uk) |
| IS (1) | IS5582A (uk) |
| MY (1) | MY123908A (uk) |
| NO (1) | NO315703B1 (uk) |
| NZ (1) | NZ506598A (uk) |
| OA (1) | OA11530A (uk) |
| PL (1) | PL342726A1 (uk) |
| SK (1) | SK13002000A3 (uk) |
| TR (1) | TR200002542T2 (uk) |
| UA (1) | UA71906C2 (uk) |
| WO (1) | WO1999044994A1 (uk) |
| YU (1) | YU52000A (uk) |
| ZA (1) | ZA994406B (uk) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| WO2001079173A2 (en) | 2000-04-17 | 2001-10-25 | Celltech R & D Limited | Enamine derivatives as cell adhesion molecules |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| US6921767B2 (en) * | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
| EP1305291A1 (en) | 2000-08-02 | 2003-05-02 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| EP1572210A1 (en) * | 2002-12-20 | 2005-09-14 | Pharmacia Corporation | The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| CA2612979A1 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
| CN101687040A (zh) | 2007-03-01 | 2010-03-31 | 马林克罗特公司 | 整合光活性的小分子及其用途 |
| JP4792124B1 (ja) * | 2010-11-15 | 2011-10-12 | エフイートレード株式会社 | 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法 |
| MX2015000794A (es) | 2012-07-18 | 2015-10-12 | Univ Saint Louis | Derivados de aminoácido beta como antagonistas de integrina. |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
| WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| CN112299983B (zh) * | 2014-06-04 | 2024-05-17 | 孟山都技术公司 | 3,6-二氯水杨酸化合物以及相关合成方法 |
| CN108779077A (zh) | 2015-12-30 | 2018-11-09 | 圣路易斯大学 | 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物 |
| US20230192661A1 (en) | 2020-05-14 | 2023-06-22 | Ube Corporation | 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
| WO2023085396A1 (ja) | 2021-11-12 | 2023-05-19 | Ｕｂｅ株式会社 | アルポート症候群を治療または予防するための医薬組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1085980C (zh) * | 1995-08-30 | 2002-06-05 | G·D·瑟尔公司 | 间－胍基、脲基、硫脲基或氮杂环氨基苯甲酸衍生物用作整合素拮抗剂 |
-
1999
- 1999-02-11 ZA ZA9904406A patent/ZA994406B/xx unknown
- 1999-02-22 TR TR2000/02542T patent/TR200002542T2/xx unknown
- 1999-02-22 WO PCT/US1999/003281 patent/WO1999044994A1/en not_active Application Discontinuation
- 1999-02-22 PL PL99342726A patent/PL342726A1/xx unknown
- 1999-02-22 YU YU52000A patent/YU52000A/sh unknown
- 1999-02-22 IL IL13765399A patent/IL137653A0/xx unknown
- 1999-02-22 JP JP2000534538A patent/JP2002505323A/ja active Pending
- 1999-02-22 EA EA200000804A patent/EA200000804A1/ru unknown
- 1999-02-22 EE EEP200000506A patent/EE200000506A/xx unknown
- 1999-02-22 OA OA1200000238A patent/OA11530A/en unknown
- 1999-02-22 NZ NZ506598A patent/NZ506598A/en unknown
- 1999-02-22 AP APAP/P/2000/001893A patent/AP1244A/en active
- 1999-02-22 BR BR9908470-8A patent/BR9908470A/pt not_active Application Discontinuation
- 1999-02-22 SK SK1300-2000A patent/SK13002000A3/sk unknown
- 1999-02-22 CA CA002322207A patent/CA2322207A1/en not_active Abandoned
- 1999-02-22 AU AU32947/99A patent/AU753230B2/en not_active Ceased
- 1999-02-22 KR KR1020007009774A patent/KR20010041584A/ko not_active Application Discontinuation
- 1999-02-22 CN CNB998035815A patent/CN1214011C/zh not_active Expired - Fee Related
- 1999-02-22 HU HU0100865A patent/HUP0100865A3/hu unknown
- 1999-02-22 UA UA2000095148A patent/UA71906C2/uk unknown
- 1999-02-22 ID IDW20001695A patent/ID25591A/id unknown
- 1999-02-22 GE GEAP19995537A patent/GEP20033118B/en unknown
- 1999-02-22 EP EP99937927A patent/EP1060164A1/en active Pending
- 1999-03-02 AR ARP990100880A patent/AR018139A1/es unknown
- 1999-03-03 MY MYPI99000772A patent/MY123908A/en unknown
-
2000
- 2000-08-04 IS IS5582A patent/IS5582A/is unknown
- 2000-08-30 NO NO20004316A patent/NO315703B1/no not_active IP Right Cessation
- 2000-09-01 BG BG104740A patent/BG104740A/xx unknown
- 2000-09-01 HR HR20000574A patent/HRP20000574A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR018139A1 (es) | 2001-10-31 |
| TR200002542T2 (tr) | 2001-05-21 |
| IS5582A (is) | 2000-08-04 |
| YU52000A (sh) | 2003-02-28 |
| WO1999044994A1 (en) | 1999-09-10 |
| AU753230B2 (en) | 2002-10-10 |
| HUP0100865A3 (en) | 2001-11-28 |
| AP1244A (en) | 2004-02-04 |
| JP2002505323A (ja) | 2002-02-19 |
| HUP0100865A2 (hu) | 2001-08-28 |
| BG104740A (en) | 2001-02-28 |
| BR9908470A (pt) | 2000-12-05 |
| UA71906C2 (en) | 2005-01-17 |
| NO20004316D0 (no) | 2000-08-30 |
| ID25591A (id) | 2000-10-19 |
| SK13002000A3 (sk) | 2001-07-10 |
| EA200000804A1 (ru) | 2001-04-23 |
| NO20004316L (no) | 2000-11-06 |
| AP2000001893A0 (en) | 2000-09-30 |
| AU3294799A (en) | 1999-09-20 |
| NO315703B1 (no) | 2003-10-13 |
| HRP20000574A2 (en) | 2001-08-31 |
| CA2322207A1 (en) | 1999-09-10 |
| ZA994406B (en) | 2000-02-11 |
| GEP20033118B (en) | 2003-11-25 |
| PL342726A1 (en) | 2001-07-02 |
| CN1214011C (zh) | 2005-08-10 |
| EP1060164A1 (en) | 2000-12-20 |
| MY123908A (en) | 2006-06-30 |
| CN1291978A (zh) | 2001-04-18 |
| KR20010041584A (ko) | 2001-05-25 |
| EE200000506A (et) | 2002-04-15 |
| OA11530A (en) | 2004-05-17 |
| IL137653A0 (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1244A (en) | Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists. | |
| AU765294B2 (en) | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists | |
| CA2250586C (en) | Meta-substituted phenylene sulphonamide derivatives | |
| CA2250695A1 (en) | Cyclopropyl alkanoic acid derivatives | |
| JP2000510098A (ja) | 桂皮酸誘導体 | |
| US6372719B1 (en) | ανβ3 integrin antagonists in combination with chemotherapeutic agents | |
| MXPA05006732A (es) | El isomero r de compuesto de beta-aminoacido como derivados de antagonistas de receptor de la integrina. | |
| US6013651A (en) | Meta-azacyclic amino benzoic acid compounds and derivatives thereof | |
| US6689754B1 (en) | Heterocyclic glycyl β-alanine derivatives | |
| EP1156999B1 (en) | Method for the preparation of a chiral-beta-amino ester | |
| US6720327B2 (en) | Lactone integrin antagonists | |
| MXPA00008427A (en) | Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists | |
| US20040019206A1 (en) | Lactone integrin antagonists | |
| US20080064716A1 (en) | Biphenyl Integrin Antagonists | |
| MXPA00009967A (en) | Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists | |
| CZ20003218A3 (cs) | Deriváty meta-azacyklické aminobenzoové kyseliny a jejich deriváty, které jsou antagonisty integrinu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |